World Health Organization (WHO) defines pharmacovigilance as âthe science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drugrelated problemâ. Once a drug is released in the market by FDA, it is monitored for its safety profile. Further, the adverse effects caused by the drug are reported to generate post-marketing surveillance data. Lipika Chablani, Pharmacovigilance of Biosimilars.
Last date updated on June, 2014